Beam Therapeutics Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted sum-of-parts (pipeline rNPV plus net cash), not a standard revenue DCF, since the company is pre-commercial: net cash of $1.2B, plus risk-adjusted pipeline value of $2,100M for risto-cel (sickle cell, ~$700M probability-weighted peak-sales estimate at 70% approval odds x a 3x peak-sales multiple), $840M for BEAM-302 (Alpha-1 Antitrypsin Deficiency, ~$280M probability-weighted peak sales at 35% approval odds x 3x), and $300M for residual base-editing platform/partnership optionality; total ~$4.44B pipeline value divided across 102M shares

Reasoning: A standard growth-rate DCF is not meaningful for a company with almost no product revenue; a probability-weighted (risk-adjusted) valuation of the two lead clinical programs plus the company's large cash cushion is the more appropriate method for a late-preclinical/early-clinical gene-editing biotech, consistent with how the sell-side and specialist biotech investors typically value pipeline-stage assets